144 related articles for article (PubMed ID: 30353975)
1. Identification and Biological Evaluation of Novel Type II B-Raf
Wang PF; Wang ZF; Qiu HY; Huang Y; Hu HM; Wang ZC; Zhu HL
ChemMedChem; 2018 Dec; 13(23):2558-2566. PubMed ID: 30353975
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of new B-Raf
Wang PF; Zhang YJ; Wang D; Hu HM; Wang ZC; Xu C; Qiu HY; Zhu HL
Bioorg Med Chem; 2018 May; 26(9):2372-2380. PubMed ID: 29602674
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
[TBL] [Abstract][Full Text] [Related]
4. Design of potent B-Raf
Wang ZF; Wang PF; Ma JT; Chai YZ; Hu HM; Gao WL; Wang ZC; Wang BZ; Zhu HL
Chem Biol Drug Des; 2018 Feb; 91(2):567-574. PubMed ID: 29045039
[TBL] [Abstract][Full Text] [Related]
5. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
[TBL] [Abstract][Full Text] [Related]
7. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel B-Raf
Wang PF; Qiu HY; Wang ZF; Zhang YJ; Wang ZC; Li DD; Zhu HL
Biochem Pharmacol; 2017 May; 132():63-76. PubMed ID: 28267440
[TBL] [Abstract][Full Text] [Related]
9. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF
Li HL; Su MM; Xu YJ; Xu C; Yang YS; Zhu HL
Eur J Med Chem; 2018 Jul; 155():725-735. PubMed ID: 29940463
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition.
Jung H; Kim J; Im D; Moon H; Hah JM
Bioorg Med Chem Lett; 2019 Feb; 29(4):534-538. PubMed ID: 30630714
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.
Li X; Shen J; Tan L; Zhang Z; Gao D; Luo J; Cheng H; Zhou X; Ma J; Ding K; Lu X
Bioorg Med Chem Lett; 2016 Jun; 26(12):2760-2763. PubMed ID: 27155899
[TBL] [Abstract][Full Text] [Related]
12. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
[TBL] [Abstract][Full Text] [Related]
14. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.
Dong JJ; Li QS; Wang SF; Li CY; Zhao X; Qiu HY; Zhao MY; Zhu HL
Org Biomol Chem; 2013 Oct; 11(37):6328-37. PubMed ID: 23942809
[TBL] [Abstract][Full Text] [Related]
16. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
[TBL] [Abstract][Full Text] [Related]
18. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers.
Lu B; Cao H; Cao J; Huang S; Hu Q; Liu D; Shen R; Shen X; Tao W; Wan H; Wang D; Yan Y; Yang L; Zhang J; Zhang L; Zhang L; Zhang M
Bioorg Med Chem Lett; 2016 Feb; 26(3):819-823. PubMed ID: 26739779
[TBL] [Abstract][Full Text] [Related]
19. Discovery of highly potent V600E-B-RAF kinase inhibitors: Molecular modeling study.
Tarazi H; El-Gamal MI; Oh CH
Bioorg Med Chem; 2019 Feb; 27(4):655-663. PubMed ID: 30660499
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
